



## Pharmacology of HIV Treatment and Antivirals against Hepatitis Viruses

Guest Editor:

**Dr. José Vicente Fernández-Montero**

Department of Internal Medicine,  
Complejo Hospitalario  
Universitario de Santiago (CHUS),  
Santiago de Compostela, Spain

Deadline for manuscript  
submissions:

**31 October 2024**

### Message from the Guest Editor

Dear Colleagues,

Therapies for HIV infection and hepatitis C have significantly evolved in recent years. Newer antiretrovirals have overcome significant obstacles like side effects, high daily pill burden, lack of efficacy, resistances, or limited access to therapy, and now, most patients receive simple therapies, mostly consisting of single-tablet regimens or long-acting injectable drugs, achieving long-lasting virological response. Furthermore, HIV might also benefit from monoclonal antibodies, which may dramatically change HIV therapy as we currently know. Direct-acting antivirals for hepatitis C infection have radically changed millions of patients' lives worldwide, achieving remarkable efficacy with short, simple treatment regimens. This therapeutic revolution has turned a complex chronic infection with limited treatment options into an eradicable disease, as seen in several population-scale trials. The development of new antivirals for hepatitis B and D offers hope for patients seeking a cure.

This Special Issue aims to provide updated information on new antiretrovirals and antivirals against hepatitis viruses, as well as newer treatment strategies and drug delivery methods.





an Open Access Journal by MDPI

## Editor-in-Chief

### Dr. Eric O. Freed

Director, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

## Message from the Editor-in-Chief

*Viruses* (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, AGRIS, and other databases.**

**Journal Rank:** JCR - Q2 (*Virology*) / CiteScore - Q1 (Infectious Diseases)

## Contact Us

---

Viruses Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/viruses](http://mdpi.com/journal/viruses)  
[viruses@mdpi.com](mailto:viruses@mdpi.com)  
[X@VirusesMDPI](https://twitter.com/VirusesMDPI)